Summary

• Idexx Laboratories, Inc. and Zoetis Inc. are dominant players in animal health, but IDXX outperforms due to superior capital efficiency and a recurring revenue flywheel.
• ZTS trades at a much lower valuation with solid margins and a dependable pipeline but requires catalysts—like EPS beats or new approvals—for rerating in 2026.
• IDXX commands a premium valuation, driven by high ROIC (37–49%) and robust growth in diagnostics, notably its Cancer DX test and InVue DX instrument adoption.
• I rate both as long-term Buys: ZTS offers value and income, while IDXX is a compounding powerhouse, though a better entry point may emerge.

Idexx Laboratories, Inc. (IDXX) and Zoetis Inc. (ZTS) are two leading publicly traded companies in animal health, spanning household pets and livestock. They operate in similar areas, which makes them worthy of comparison as investments.

Zoetis is based in Parsippany, NJ, and IPO’d as a Pfizer (PFE) spinoff in 2013. Idexx Laboratories (hereafter Idexx) is based in Westbrook, ME, and was founded in 1983; it IPO’d in 1991. This is my first coverage of Idexx, but I have covered Zoetis on three previous occasions.

In my first ZTS coverage, a kind of deep dive on the company, I noted revenue growth had slowed in the post-Covid environment, but I felt this would be offset by Zoetis benefitting from the long-term secular tailwinds of rising pet ownership and their pivotal position in this industry. They enjoyed strong margins and rising revenue. Despite shares falling, I upgraded Zoetis to a Strong Buy in July 2025, citing their growing market share, improving revenue and margins, and multi-year low valuation. Shares were priced around $150 at the time. I reiterated my strong buy rating in my last coverage in November 2025, with shares basically flat versus a 5% gain for the S&P 500.

As a ZTS shareholder and analyst, this has been a poor investment and analyst call. I welcome the opportunity to take another stab at this company, and as a means of trying to understand where I went wrong, I offer a comparison to Idexx, which has enjoyed a much stronger performance. By comparing their offerings, business models, and finances, I hope to develop a better understanding of them as companies and investments in terms of risk/reward.

In this comparative analysis, I’ll assess secular growth trends alongside their respective product lines. I’ll also pay very close attention to financial and valuation metrics in light

1.04K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ZTS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.